Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7057 USD | +3.60% | -3.01% | -1.58% |
14/05 | Transcript : VolitionRx Limited, Q1 2024 Earnings Call, May 14, 2024 | |
13/05 | VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.58% | 58.45M | C | ||
-38.56% | 8.39B | A- | ||
+0.18% | 3.32B | C | ||
+9.29% | 2.48B | D+ | ||
-18.21% | 2.06B | - | B- | |
-24.57% | 1.59B | C+ | ||
+32.37% | 1.15B | B- | ||
-7.64% | 704M | C+ | ||
+8.42% | 678M | C- | ||
-29.59% | 508M | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VNRX Stock
- Ratings VolitionRx Limited